US Stock MarketDetailed Quotes
TERN Terns Pharmaceuticals
- 8.790
- +0.120+1.38%
Close Jul 25 16:00 ET
- 8.940
- +0.150+1.71%
Post 20:02 ET
568.51MMarket Cap-6976P/E (TTM)
9.240High8.620Low1.21MVolume8.750Open8.670Pre Close10.83MTurnover5.97%Turnover RatioLossP/E (Static)64.68MShares10.03052wk High2.40P/B177.59MFloat Cap3.26052wk Low--Dividend TTM20.20MShs Float28.360Historical High--Div YieldTTM7.15%Amplitude1.450Historical Low8.974Avg Price1Lot Size
Terns Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -58.52%-22.8M | -37.23%-67.39M | -72.30%-19.32M | -54.06%-20.7M | -16.40%-12.99M | -8.14%-14.38M | -17.41%-49.11M | -5.08%-11.21M | -66.25%-13.44M | -27.42%-11.16M |
| Net income from continuing operations | -3.93%-22.37M | -49.49%-90.21M | -32.85%-21.02M | -76.97%-29.77M | -28.47%-17.9M | -56.31%-21.53M | -20.31%-60.35M | -11.05%-15.82M | -42.12%-16.82M | -29.73%-13.93M |
| Depreciation and amortization | 6.31%236K | -14.63%881K | -5.58%220K | -11.90%222K | -19.33%217K | -20.14%222K | 101.56%1.03M | 104.39%233K | 135.51%252K | 126.05%269K |
| Deferred tax | 6.25%34K | -64.03%141K | -87.25%45K | 128.57%32K | 700.00%32K | 52.38%32K | 79.00%392K | 102.87%353K | 100.00%14K | -81.82%4K |
| Change In working capital | -216.04%-4.36M | 224.49%1.29M | -118.12%-345K | -868.56%-3.52M | 746.30%1.4M | 218.13%3.76M | 27.23%-1.04M | 248.08%1.9M | -63.33%458K | 4.00%-216K |
| -Change in prepaid assets | -1,764.18%-1.25M | -71.36%-1.92M | -111.61%-137K | -148.48%-1.14M | -1,203.85%-574K | 96.46%-67K | -571.01%-1.12M | 87.60%1.18M | -342.11%-460K | -92.27%52K |
| -Change in payables and accrued expense | -173.66%-2.94M | 458.79%3.88M | -104.32%-38K | -304.83%-2.21M | 1,861.98%2.13M | 449.69%3.99M | 142.32%694K | 899.09%879K | 0.19%1.08M | 86.08%-121K |
| -Change in other current liabilities | -7.36%-175K | -9.18%-666K | -9.68%-170K | -7.55%-171K | -10.20%-162K | -9.40%-163K | ---610K | ---155K | ---159K | ---147K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -58.52%-22.8M | -37.23%-67.39M | -72.30%-19.32M | -54.06%-20.7M | -16.40%-12.99M | -8.14%-14.38M | -17.41%-49.11M | -5.08%-11.21M | -66.25%-13.44M | -27.42%-11.16M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -71.37%8M | -70.56%-37.99M | 424.71%47.23M | -1,699.44%-22.31M | -468.66%-90.84M | 194.38%27.93M | 81.39%-22.27M | -126.54%-14.55M | -127.91%-1.24M | 23.58%-15.97M |
| Net PPE purchase and sale | ---29K | 81.09%-52K | -29.41%-44K | -200.00%-8K | --0 | --0 | 19.12%-275K | 83.00%-34K | 110.81%8K | 83.33%-7K |
| Net investment purchase and sale | -71.26%8.03M | -72.46%-37.94M | 425.77%47.28M | -1,687.26%-22.31M | -468.90%-90.84M | 187.06%27.93M | 81.57%-22M | -133.27%-14.51M | -127.63%-1.25M | 23.46%-15.97M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -71.37%8M | -70.56%-37.99M | 424.71%47.23M | -1,699.44%-22.31M | -468.66%-90.84M | 194.38%27.93M | 81.39%-22.27M | -126.54%-14.55M | -127.91%-1.24M | 23.58%-15.97M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | -74.89%41.95M | -86.92%13.86M | -99.97%20K | 294.35%489K | 27.58M | 24.33%167.1M | 662,212.50%105.97M | 7,553.83%61M | 107.80%124K |
| Net common stock issuance | --0 | -75.12%41.61M | -87.10%13.69M | --0 | --0 | --27.92M | 22.65%167.25M | --106.11M | --61.15M | --0 |
| Proceeds from stock option exercised by employees | ---- | 181.48%684K | 47.06%175K | --20K | ---- | ---- | -73.41%243K | 643.75%119K | --0 | ---- |
| Net other financing activities | ---- | 14.21%-344K | --0 | --0 | --0 | ---344K | -104.01%-401K | ---257K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | -74.89%41.95M | -86.92%13.86M | -99.97%20K | 294.35%489K | --27.58M | 24.33%167.1M | 662,212.50%105.97M | 7,553.83%61M | 107.80%124K |
| Net cash flow | ||||||||||
| Beginning cash position | -44.20%79.93M | 200.29%143.24M | -39.83%37.89M | 381.49%80.92M | 320.14%184.35M | 200.29%143.24M | -36.28%47.7M | -2.74%62.98M | -75.14%16.81M | -55.60%43.88M |
| Current changes in cash | -135.99%-14.8M | -166.27%-63.43M | -47.92%41.78M | -192.81%-42.99M | -282.57%-103.34M | 1,178.93%41.13M | 452.80%95.71M | 569.80%80.21M | 1,730.01%46.33M | 13.56%-27.01M |
| Effect of exchange rate changes | -160.00%-26K | 165.73%117K | 466.67%255K | 77.92%-34K | -54.10%-94K | -25.00%-10K | -612.00%-178K | 104.55%45K | -3,950.00%-154K | -654.55%-61K |
| End cash Position | -64.69%65.1M | -44.20%79.93M | -44.20%79.93M | -39.83%37.89M | 381.49%80.92M | 320.14%184.35M | 200.29%143.24M | 200.29%143.24M | -2.74%62.98M | -75.14%16.81M |
| Free cash flow | -58.72%-22.83M | -36.57%-67.44M | -72.17%-19.36M | -54.21%-20.71M | -16.33%-12.99M | -6.20%-14.38M | -17.12%-49.38M | -3.46%-11.25M | -64.64%-13.43M | -26.89%-11.17M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg